

## **HHS Public Access**

Author manuscript *Am J Cardiol*. Author manuscript; available in PMC 2020 September 16.

Published in final edited form as:

Am J Cardiol. 2020 March 01; 125(5): 812–819. doi:10.1016/j.amjcard.2019.12.001.

### Assessing Pregnancy, Gestational Complications, and Comorbidities in Women With Congenital Heart Defects (Data from ICD-9-CM Codes in 3 US Surveillance Sites)

Cheryl Raskind-Hood, MPH, MS<sup>a</sup>, Anita Saraf, MD, PhD<sup>a</sup>, Tiffany Riehle-Colarusso, MD, MPH<sup>b</sup>, Jill Glidewell, MSN, MPH<sup>b</sup>, Michelle Gurvitz, MD MS<sup>c</sup>, Julie E. Dunn, PhD<sup>c</sup>, George K. Lui, MD<sup>d</sup>, Alissa Van Zutphen, PhD<sup>e,f</sup>, Claire McGarry, MPH<sup>e</sup>, Carol J. Hogue, PhD, MPH<sup>a</sup>, Trenton Hoffman, MS<sup>a</sup>, Fred H. Rodriguez III, MD<sup>a</sup>, Wendy M. Book, MD<sup>a,\*</sup>

<sup>a</sup>Emory University School of Medicine and Rollins School of Public Health, Atlanta, Georgia

<sup>b</sup>National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia

<sup>c</sup>Massachusetts Department of Public Health, Boston, Massachusetts

<sup>d</sup>Stanford University School of Medicine, Stanford, California

DCDD Replication Statement

This analysis has undergone replication by Trenton Hoffman.

#### Supplementary materials

Supplementary material associated with this article can be found in the online version at https://doi.org/10.1016/j.amjcard.2019.12.001.

Disclosures

The authors have no conflicts of interest to disclose.

<sup>&</sup>lt;sup>\*</sup>Corresponding author: Tel: 404-778-5545; fax: 404-778-5035. wbook@emory.edu (W.M. Book). Authors' contributions

**Cheryl Raskind-Hood, MPH, MS:** Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Supervision; Validation; Visualization; Roles/Writing - original draft; Writing - review & editing.

Anita Saraf, MD, PhD: Conceptualization; Investigation; Methodology; Project administration; Resources; Software; Supervision; Visualization; Roles/Writing - original draft; Writing - review & editing.

**Tiffany Riehle-Colarusso, MD, MPH:** Conceptualization; Investigation; Methodology; Project administration; Resources; Supervision; Visualization; Roles/Writing - original draft; Writing - review & editing.

**Jill Glidewell**, **MSN**, **MPH**: Conceptualization; Investigation; Methodology; Project administration; Resources; Supervision; Validation; Visualization; Roles/Writing - original draft; Writing - review & editing.

Michelle Gurvitz, MD, MS: Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Supervision; Validation; Visualization; Roles/Writing - original draft; Writing - review & editing. Julie E. Dunn, PhD: Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Supervision; Validation; Visualization; Roles/Writing - original draft; Writing - review & editing. George K. Lui, MD: Conceptualization; Data curation; Funding acquisition; Investigation; Methodology; Project administration;

Resources; Validation; Roles/Writing - original draft; Writing - review & editing. Alissa Van Zutphen, PhD: Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Supervision; Validation; Roles/Writing - original draft; Writing - review & editing.

**Claire McGarry, MPH:** Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Supervision; Validation; Roles/Writing - original draft; Writing - review & editing.

Carol J. Hogue, PhD, MPH: Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Supervision; Validation; Visualization; Roles/Writing - original draft; Writing - review & editing. Trenton Hoffman, MS: Conceptualization; Formal analysis; Methodology; Project administration.

Fred H. Rodriguez III, MD: Conceptualization; Data curation; Investigation; Methodology; Project administration; Resources; Supervision; Visualization; Roles/Writing - original draft; Writing - review & editing.

**Wendy M. Book, MD:** Conceptualization; Data curation; Funding acquisition; Investigation; Methodology; Project administration; Resources; Supervision; Visualization; Roles/Writing - original draft; Writing - review & editing.

Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

<sup>e</sup>New York State Department of Health, Albany, New York

<sup>f</sup>University at Albany School of Public Health, Rensselaer, New York.

#### Abstract

Improved treatment of congenital heart defects (CHDs) has resulted in women with CHDs living to childbearing age. However, no US population-based systems exist to estimate pregnancy frequency or complications among women with CHDs. Cases were identified in multiple data sources from 3 surveillance sites: Emory University (EU) whose catchment area included 5 metropolitan Atlanta counties; Massachusetts Department of Public Health (MA) whose catchment area was statewide; and New York State Department of Health (NY) whose catchment area included 11 counties. Cases were categorized into one of 5 mutually exclusive CHD severity groups collapsed to severe versus not severe; specific ICD-9-CM codes were used to capture pregnancy, gestational complications, and nongestational co-morbidities in women, age 11 to 50 years, with a CHD-related ICD-9-CM code. Pregnancy, CHD severity, demographics, gestational complications, co-morbidities, and insurance status were evaluated. ICD-9-CM codes identified 26,655 women with CHDs, of whom 5,672 (21.3%, range: 12.8% in NY to 22.5% in MA) had codes indicating a pregnancy. Over 3 years, age-adjusted proportion pregnancy rates among women with severe CHDs ranged from 10.0% to 24.6%, and 14.2% to 21.7% for women with nonsevere CHDs. Pregnant women with CHDs of any severity, compared with nonpregnant women with CHDs, reported more noncardiovascular co-morbidities. Insurance type varied by site and pregnancy status. These US population-based, multisite estimates of pregnancy among women with CHD indicate a substantial number of women with CHDs may be experiencing pregnancy and complications. In conclusion, given the growing adult population with CHDs, reproductive health of women with CHD is an important public health issue.

Congenital heart defects (CHDs) vary in phenotypes and outcomes,<sup>1</sup> with adults now comprising an estimated 2/3 of individuals with CHDs.<sup>2</sup> Annual deliveries for women with CHDs increased 34.9% from 1998 to 2007, compared with 21.3% in the general population. <sup>3</sup> Since pregnant women with CHDs face increased risk of maternal complications and mortality,<sup>4</sup> data on pregnancies and their outcomes are needed to assist women with CHDs with reproductive decisions. Countries with national databases can prospectively track cohorts of pregnant women with CHDs,<sup>5</sup> making it possible to estimate maternal risks in pregnancy.<sup>6–8</sup> However, international databases do not reflect the diversity and healthcare patterns in the United States. Pregnancy outcomes are likely influenced by socioeconomic standing, healthcare access, provider knowledge, and chronic conditions.<sup>9–11</sup> We analyzed data from 3 US surveillance sites to estimate the proportion of women with CHDs who became pregnant, their co-morbidities, insurance status, and gestational complications.

#### Methods

This analysis was a component of a larger CDC surveillance project of adolescents and adults with CHDs at 3 funded US sites: EU (Atlanta, GA), MA, and NY (Centers for Disease Control and Prevention, Grant/Award Number: CDC–RFA–DD12–1207). Overall project methods are described in a separate methods paper.<sup>12</sup> For this analysis, cases were

females aged 11 to 50 years (adolescents 11 to 19 years, adults 20 to 50 years), who resided in site-specific catchment areas: 5 metropolitan Atlanta counties for EU, 11 counties across NY state, and statewide for MA. All cases were presumed alive as of January 1, 2010, and had at least one healthcare encounter with an eligible CHD *International Classification of Disease version 9.0 Clinical Modification* (ICD-9-CM) code between January 1, 2008 (January 1, 2009 for MA) and December 31, 2010. Data sources included outpatient clinics, Medicaid claims, outpatient and hospital encounter data, and information from supplemental sources including state vital records (EU, MA), and birth defects registries (EU, NY). Participating sites had varying populations and data sources, completeness, and linkage methodologies.<sup>12</sup>

Cases identified as previously described<sup>12</sup> were categorized into one of 5 mutually exclusive hierarchical groups based on anatomy: severe, shunt, valve, shunt plus valve, and other CHDs.<sup>12,13</sup> The latter 4 categories were grouped as "not severe" for comparison to severe. The severe group included CHDs that typically require surgery in the first year of life such as pulmonary atresia, tetralogy of Fallot, or single ventricle defects.<sup>12</sup> We excluded cases that had 745.5 code (secundum atrial septal defect or patent foramen ovale) without other specific CHD codes because 745.5 frequently includes persons without CHDs.<sup>14</sup>

We used Clinical Classification Software (CCS), developed by the Agency for Healthcare Research and Quality (AHRQ) to categorize non-CHD administrative codes. CCS collapses over 15,000 ICD-9-CM diagnostic and 3,900 procedure codes into clinical categories.<sup>15</sup> We identified females who experienced pregnancies during the specified time period ('pregnant women') by the presence of at least one of 1,520 ICD-9-CM codes that were collapsed into 27 CCS categories (eTable A) occurring at any time during a woman's 2008 to 2010 encounter history. Pregnancy onset and outcome were not available; therefore the timing and frequency of pregnancies for an individual woman could not be determined. Project clinicians identified, categorized and grouped non-CHD ICD-9-CM codes into maternal gestational complications based on individual ICD-9-CM codes for pregnancy or postpartum-specific conditions (eTable B) and into comorbidity categories not necessarily related to pregnancy (eTable C).<sup>15</sup> For instance, ICD-9-CM codes 642.00-642.34 and 642.90-4 are used for gestational hypertension, and codes 401.1 and 401.9 are used for essential hypertension. Clinicians categorized gestational complications, and nongestational co-morbid conditions into cardiovascular and noncardiovascular categories for analysis. We assessed cases with a fetal echocardiogram Current Procedural Terminology (CPT) code (76825–8) for the presence of a CHD code outside of the fetal echocardiogram encounters to distinguish maternal CHD from potential CHD in their fetus.

Identified cases could have multiple healthcare encounters in several data sources. We combined, de-identified, and de-duplicated encounter and summary data to create a common collaborative analytic dataset across sites. We classified insurance status, based on primary health insurance type for the healthcare encounter nearest to January 1, 2010 into 4 categories: (1) self-pay/uninsured; (2) private/commercial; (3) government-based [Medicaid, Medicare/Social Security Income (SSI), Tricare]; and (4) other.

We conducted all analyses, except the age-adjusted proportion pregnant, using Statistical Analysis System (SAS) 9.4 TM Level IM5, w32\_10Pro platform.<sup>16</sup> Frequencies, percentages, and chi-square analyses of major categorical variables including CHD severity, age, pregnancy status (between 2008 and 2010), and insurance were conducted by site and pooled across sites. Chi-square analyses were used to compare frequencies of cardiovascular and noncardiovascular gestational complications and co-morbidities by CHD status, site and pregnancy status. To control for effects of maternal age on gestational complications and co-morbidities unrelated to pregnancy, sensitivity analyses were conducted constraining age to 20 to 35 year olds. Chi-square tests were computed to analyze the association of CHD severity with gestational cardiovascular and noncardiovascular complications. While crude pregnancy proportion is a useful summary measure comparing similar populations of different sizes, it is sensitive to differences in age distribution. Thus, we calculated age-adjusted proportion pregnant, which adjusts for the observed differences in age distributions across sites.

#### Results

During the project period, 26,655 females, ages 11 to 50 years, had at least 1 healthcare encounter with 1 or more CHD ICD-9-CM codes. Of these, 5672 (21.3%) had at least 1 pregnancy-related code (Table 1). Overall, EU had a higher proportion of females with severe CHDs (30.7%) compared with MA (17.8%) and NY (19.3%), regardless of pregnancy status (data not shown). Among women with severe CHD, NY had the lowest age-adjusted proportion pregnant and MA had the highest age-adjusted proportion (Table 1). EU had the same age-adjusted proportion pregnant irrespective of CHD severity. EU and NY sites had similar proportions of gestational cardiovascular complications including gestational hypertension, pre-eclampsia, and other cardiovascular complications, while MA had few pregnancy-related cardiovascular complications. Noncardiovascular complications among pregnant women varied across sites, including preterm labor, anemia, and hemorrhage (Table 2). Pooled across site and severity, pregnant women compared with nonpregnant women had significantly more nongestational cardiovascular co-morbidities including essential hypertension, hyperlipidemia, coronary artery disease, and venous disorder/phlebitis (Table 3). Differences in cardiovascular co-morbidities for pregnant compared with nonpregnant women varied by site (Table 3). While hypertension, hyperlipidemia, coronary artery disease, and venous disorder/phlebitis were more frequent among pregnant women compared with those who were not in MA and EU, this pattern was not seen in NY (Table 3). Pooled across site and severity, pregnant women compared with nonpregnant women also had significantly more nongestational noncardiovascular comorbidities, including nongestational diabetes mellitus, hematologic conditions, gastrointestinal conditions, respiratory and pulmonary problems, infectious diseases, and genitourinary/gynecology problems (Table 4).

A sensitivity analysis conducted to assess the effect of maternal age on co-morbidities with a constrained sample of 20 to 35 year olds mimicked findings from the full sample. Similar results to those in Table 3 were revealed for hypertension (28.6% vs 20.8%), hyperlipidemia (17.8% vs 14.5%), coronary artery disease (10.0% vs 8.2%), and venous disorder/phlebitis (5.9% vs 4.4%) with pregnant women with severe CHDs having significantly more

nongestational cardiovascular co-morbidities compared with nonpregnant women with CHDs (data not shown). Pregnant women compared with nonpregnant women had significantly more nongestational, noncardiovascular co-morbidities, including diabetes mellitus, hematologic conditions, infectious diseases, and genitourinary/gynecology problems (Table 4). Pregnant women with severe CHD compared with those with not severe CHD more often had nongestational diabetes mellitus (28.3% vs 22.5%, p <0.0001), hematologic conditions (25.8% vs 21.7%, p <0.01), neurologic problems (14.7% vs 12.1%, p <0.05), and mental health problems (52.0% vs 40.5%, p <0.0001) (data not shown). Fewer than 2.5% of pregnancy cases had a CHD diagnosis code associated only with a fetal echocardiogram encounter.

Figure 1 shows observed differences in insurance across sites for pregnant and nonpregnant women. While government-based insurance was more common among pregnant compared with nonpregnant women at both EU and MA, EU had more than a 2-fold higher difference between pregnant and nonpregnant women compared with MA. In MA, most women regardless of pregnancy status had government-based health insurance. In NY, private insurance was most common for both pregnant and nonpregnant women (Figure 1).

#### Discussion

Through identification of pregnancy-related ICD-9-CM codes in clinical and administrative databases, we identified approximately 13% to 23% of females with CHD of childbearing age to have experienced a pregnancy from 2008 to 2010 surveillance data at 3 US sites. While our project methodology is not directly comparable to US population norms, our data suggest a substantial number of women with CHD are experiencing pregnancy. In this analysis, pregnant women with CHD experienced complications at a greater rate than previously reported by population norms.<sup>17–20</sup> The proportion of pregnant women was greater in MA (22.5% in MA compared with 13% to 14% at the other 2 sites). Fewer gestational complications were found among those in MA compared with the other sites, and were below previously published US population norms,<sup>20–22</sup> thus discussion focuses on EU and NY.

Pregnancy among women with severe CHDs more often involved several gestational complications compared with pregnancy among women without severe CHDs. However, women with CHD may have a higher risk for some pregnancy related complications such as anemia, hemorrhage, and hypertension when compared with women without CHD. The percentage of pregnant women who experienced hemorrhage was similar between NY and EU and higher than a US population estimate (4.2 per 1,000 deliveries in 2008 of severe postpartum hemorrhage, based on a definition of hemorrhage treated by blood transfusion, hysterectomy, and/or surgical repair of the uterus.<sup>18</sup> Adults with CHDs treated with anticoagulants are at elevated risk of hemorrhage<sup>23</sup> and those with certain CHDs (e.g., palliative single ventricle heart defects or mechanical valve) have elevated risk of hemorrhage due to coagulation disorders.<sup>24</sup> Hypertensive disorders in the US occurred in 83.4 per 1,000 deliveries in 2006<sup>19</sup> compared with our observed prevalence of 75 to 127 per 1,000 pregnancies in NY and EU. Eclampsia or severe pre-eclampsia was 5 times the US prevalence (of 12.4 per 1,000 deliveries) among women with CHDs (65 to 73 per 1,000 in

NY and EU), suggesting women with CHDs and gestational hypertension need close monitoring. Although our analysis could not distinguish anemia severity, the rate of anemia found in women with CHD was more than double the national average for all gestational anemia.<sup>21</sup> The reason for this finding deserves further investigation, but may include anticoagulation and antiplatelet therapies. From 2008 to 2010, estimated gestational diabetes in the US was 5.6%.<sup>17</sup> State-specific estimates of gestational diabetes varied from 3.5% to 7.2% in 2008, depending on sociodemographic and healthcare factors. Gestational diabetes estimates for pregnant women with CHDs in NY and EU were 5.9% and 12.0%, respectively, suggesting similar multifactorial and geographic variation of gestational diabetes for women with CHDs.

These data support a clinical concern that CHD-related issues such as need for anticoagulation, risk for thromboembolic complications, and factors predisposing to hypertension or heart failure may contribute to a higher risk of pregnancy complications compared with population norms. Women with CHDs contemplating pregnancy should receive preconception counseling regarding maternal, obstetric, fetal, and neonatal risk. Those with severe CHDs may be best served in a tertiary referral center with maternal fetal medicine expertise. The European Society of Cardiology 2018 Guidelines are a good resource for management of specific heart defects and cardiac complications in pregnancy.<sup>4</sup>

Pregnant women with CHDs had significantly more nongestational co-morbidities than nonpregnant women with CHDs. Clinically relevant co-morbidities may be exacerbated in pregnancy, such as pre-existing heart failure.<sup>25</sup> Although we cannot discern why more nongestational co-morbidities appear in women who have been pregnant, it is possible this represents a more thorough medical history and/or more comprehensive coding in pregnant women.

Site-specific differences in insurance coverage for pregnant versus nonpregnant women with CHDs were evident in EU and MA, with proportionately more pregnant than nonpregnant women having government-based insurance; EU had the greater difference compared with MA, 48.5% pregnant versus 25.0% nonpregnant. This likely reflects state-based differences in insurance accessibility outside of pregnancy. Differences in access to insurance-paid healthcare among nonpregnant women might affect their susceptibility to complications when they do become pregnant. Substantial literature supports the need for preconception care for all women.<sup>26,27</sup> As preconception care may be less accessible in Georgia when women lack insurance outside of pregnancy, those women may enter pregnancy at elevated risk of complications due to chronic conditions such as untreated diabetes and hypertension. <sup>28</sup>

Comparability of data across sites may be limited by variability and completeness in data sources. Under- or overreporting of pregnancies may occur due to data capture by administrative codes.<sup>6</sup> We were unable to define pregnancy timing or frequency within the project period, thus temporal relation of nongestational co-morbidities to pregnancy cannot be determined. While the number of pregnant women with CHDs might have been over- or under-reported, so might the number of nonpregnant women with CHDs.

To our knowledge, this is the first US population-based, multi-site project estimating pregnancy among women with CHDs defined by coded healthcare encounters. Our findings suggest a substantial percent of women with CHDs may be experiencing gestational complications and other co-morbidities. Given the growing population of adults with CHDs, reproductive health of women of childbearing age with CHDs is an important public health issue warranting further investigation.

#### Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

#### Acknowledgment (Funding/Support)

Centers for Disease Control and Prevention, Atlanta, GA USA, Grant/Award Number: CDC RFA DD12 1207.

#### References

- 1. Mackie AS, Pilote L, Ionescu-Ittu R, Rahme E, Marelli AJ. Health care resource utilization in adults with congenital heart disease. Am J Cardiol 2007;99:839–843. [PubMed: 17350378]
- Gilboa SM, Devine OJ, Kucik JE, Oster ME, Riehle-Colarusso T, Nembhard WN, Xu P, Correa A, Jenkins K, Marelli AJ. Congenital heart defects in the United States: estimating the magnitude of the affected population in 2010. Circulation 2016;134:101–109. [PubMed: 27382105]
- Opotowsky AR, Siddiqi OK, D'Souza B, Webb GD, Fernandes SM, Landzberg MJ. Maternal cardiovascular events during childbirth among women with congenital heart disease. Heart 2012;98(2):145–151. [PubMed: 21990383]
- 4. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cífková R, De Bonis M, Iung B, Johnson MR, Kintscher U, Kranke P, Lang IM, Morais J, Pieper PG, Presbitero P, Price S, Rosano GMC, Seeland U, Simoncini T, Swan L, Warnes CA, ESC SDG. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J 2018;39:3165–3241. [PubMed: 30165544]
- 5. Roos-Hesselink J, Baris L, Johnson M, De Backer J, Otto C, Marelli A, Jondeau G, Budts W, Grewal J, Sliwa K, Parsonage W, Maggioni AP, van Hagen I, Vahanian A, Tavazzi L, Elkayam U, Boersma E, Hall R. Pregnancy outcomes in women with cardiovascular disease: evolving trends over 10 years in the ESC Registry Of Pregnancy And Cardiac disease (ROPAC). Eur Heart J 2019 3 25 10.1093/eurheartj/ehz136.
- 6. Drenthen W, Boersma E, Balci A, Moons P, Roos-Hesselink JW, Mulder BJM, Vliegen HW, van Dijk APJ, Voors AA, Yap SC, van Veldhuisen DJ, Pieper PG, Investigators ZAHARA. Predictors of pregnancy complications in women with congenital heart disease. Eur Heart J 2010;31:2124–2132. [PubMed: 20584777]
- Bonnet V, Simonet T, Labombarda F, Dolley P, Milliez P, Dreyfus M, Hanouz JL. Neonatal and maternal outcomes of pregnancy with maternal cardiac disease (the NORMANDY study): years 2000–2014. Anaesth Crit Care Pain Med 2018;37:61–65. [PubMed: 28153548]
- Silversides CK, Grewal J, Mason J, Sermer M, Kiess M, Rychel V, Wald RM, Colman JM, Siu SC. Pregnancy outcomes in women with heart disease: The CARPREG II Study. J Am Coll Cardiol 2018;71: 2419–2430. [PubMed: 29793631]
- Mackie AS, Ionescu-Ittu R, Therrien J, Pilote L, Abrahamowicz M, Marelli AJ. Children and adults with congenital heart disease lost to follow-up: who and when? Circulation 2009;120:302–309. [PubMed: 19597053]
- Admon LK, Winkelman TNA, Zivin K, Terplan M, Mhyre JM, Dalton VK. Racial and ethnic disparities in the incidence of severe maternal morbidity in the United States, 2012–2015. Obstet Gynecol 2018;132: 1158–1166. [PubMed: 30303912]

- Bruce FC, Berg CJ, Joski PJ, Roblin DW, Callaghan WM, Bulkley JE, Bachman DJ, Hornbrook MC. Extent of maternal morbidity in a managed care population in georgia. Paediatr Perinat Epidemiol 2012;26: 497–505. [PubMed: 23061685]
- Glidewell J, Book W, Raskind-Hood C, Hogue C, Dunn JE, Gurvitz M, Ozonoff A, McGarry C, Van Zutphen A, Lui G, Downing K, Riehle-Colarusso T. Population-based surveillance of congenital heart defects among adolescents and adults: surveillance methodology. Birth Defects Res 2018;110:1395–1403. [PubMed: 30394691]
- Marelli AJ, Mackie AS, Ionescu-Ittu R, Rahme E, Pilote L. Congenital heart disease in the general population: changing prevalence and age distribution. Circulation 2007;115:163–172. [PubMed: 17210844]
- Rodriguez FH, Ephrem G, Gerardin JF, Raskind-Hood C, Hogue C, Book W. The 745.5 issue in code-based, adult congenital heart disease population studies: relevance to current and future ICD-9-CM and ICD-10-CM studies. Congenit Heart Dis 2018;13:59–64. [PubMed: 29266726]
- HCUP CCS. Healthcare Cost and Utilization Project (HCUP). Rockville, MD: Agency for Healthcare Research and Quality; 3 2017 Available at: www.hcup-us.ahrq.gov/toolssoftware/ccs/ ccs.jsp.
- Institute SAS. Base SAS 9.3 Procedures Guide Statistical Procedures. Cary, N.C.: SAS Institute; 2011 Available at: http://www.books24×7.com/marc.asp?bookid=44484. Accessed November 14, 2018.
- Bardenheier BH, Elixhauser A, Imperatore G, Devlin HM, Kuklina EV, Geiss LS, Correa A. Variation in prevalence of gestational diabetes mellitus among hospital discharges for obstetric delivery across 23 states in the United States. Diabetes Care 2013;36:1209–1214. [PubMed: 23248195]
- Kramer MS, Berg C, Abenhaim H, Dahhou M, Rouleau J, Mehrabadi A, Joseph KS. Incidence, risk factors, and temporal trends in severe postpartum hemorrhage. Am J Obstet Gynecol 2013;209:449.e1–449. e7. [PubMed: 23871950]
- Kuklina EV, Ayala C, Callaghan WM. Hypertensive disorders and severe obstetric morbidity in the United States. Obstet Gynecol 2009; 113:1299–1306. [PubMed: 19461426]
- Bardenheier BH, Imperatore G, Devlin HM, Kim SY, Cho P, Geiss LS. Trends in pre-pregnancy diabetes among deliveries in 19 U.S. states, 2000–2010. Am J Prev Med 2015;48:154–161. [PubMed: 25326417]
- 21. Le CH. The Prevalence of Anemia and Moderate-Severe Anemia in the US Population (NHANES 2003–2012). PLoS One 2016;11: e0166635. [PubMed: 27846276]
- Curtin SC, Abma JC, Ventura SJ, Henshaw SK. Pregnancy rates for U. S. women continue to drop. NCHS Data Brief 2013:1–8.
- 23. Yang H, Heidendael JF, de Groot JR, Konings TC, Veen G, van Dijk APJ, Meijboom FJ, Sieswerda GT, Post MC, Winter MM, Mulder BJM, Bouma BJ. Oral anticoagulant therapy in adults with congenital heart disease and atrial arrhythmias: implementation of guidelines. Int J Cardiol 2018;257:67–74. [PubMed: 29506740]
- Monteiro RS, Dob DP, Cauldwell MR, Gatzoulis MA. Anaesthetic management of parturients with univentricular congenital heart disease and the Fontan operation. Int J Obstet Anesth 2016;28: 83– 91. [PubMed: 27726918]
- 25. Anthony J, Sliwa K. Decompensated heart failure in pregnancy. Card Fail Rev 2016;2:20–26. [PubMed: 28785449]
- 26. Robbins C, Boulet SL, Morgan I, D'Angelo DV, Zapata LB, Morrow B, Sharma A, Kroelinger CD. Disparities in preconception health indicators - behavioral risk factor surveillance system, 2013– 2015, and pregnancy risk assessment monitoring system, 2013–2014. MMWR Surveill Summ 2018;67:1–16.
- Witt WP, Mandell KC, Wisk LE, Cheng ER, Chatterjee D, Wakeel F, Park H, Zarak D. Infant birthweight in the US: the role of preconception stressful life events and substance use. Arch Womens Ment Health 2016;19:529–542. [PubMed: 26767530]
- Georgia Department of Human Services. Right from the Start Medicaid (RSM): The RSM Medicaid Program available through the Division of Family and Children Services (DFCS). Avail-

able at: http://dhs.georgia.gov/sites/dhs.georgia.gov/files/related\_files/document/DFCS.RSM %20Medicaid%205.12.pdf. Accessed September 2, 2019.



#### Figure 1.

Healthcare Insurance by pregnancy during project period for women age 11–50 years with congenital heart defects (CHD) at 3 surveillance sites, 2008 to 2010.\*\*

CHD = Congenital Heart Defect

\* EU=Emory University; catchment area includes 5 metro-Atlanta counties: Clayton, Cobb, DeKalb, Fulton and Gwinnett;

MA=Massachusetts Department of Public Health; catchment area is state-wide; and NY=New York State Department of Health; catchment area includes 11 counties: Allegany, Bronx, Cattaraugus, Chautauqua, Erie, Genesee, Monroe, Niagara, Orleans, Westchester, and Wyoming

\*\* Data collapsed across CHD severity.

^^ Individuals classified with ICD-9\_CM code 745.5 in isolation are not included. Note. Government healthcare insurance includes Medicaid, Medicare, Tricare, and Military coverage. Pregnancy during project period, by age, congenital heart defect (CHD) severity, and surveillance site, including age-adjusted proportion pregnant, for women age 11–50 years with CHD  $^{\prime\prime}$  , 2008 to 2010

		Preg	gnant	
TOTAL $(n = 26,655)$	Yes $n = 5$	,672 (21.3%)	No 20,9	983 (78.7%)
	Severe CHD 1,126 (19.8%)	Not Severe CHD 4,546 (80.2%)	Severe CHD 3,893 (18.5%)	Not Severe CHD 17,090 (81.5%)
$\mathrm{EU}^{*}\left(\mathbf{n}=1,994\right)^{A}$				
Pregnancy Status	n = 27	5 (13.8%)	n = 1,7	719 (86.2%)
	Severe CHD	Not Severe CHD	Severe CHD	Not Severe CHD
Age-Adjusted Proportion Pregnant by CHD Severity	14.2	14.2		
% Severe by Pregnancy Status	84 (30.5%)	191 (69.5%)	529 (30.8%)	1,190~(69.2%)
CHD Severity by Pregnancy Status and Age 11–19	10 (38.5%)	16 (61.5%)	261 (33.9%)	508 (66.1%)
20-29	47 (33.6%)	93 (66.4%)	148 (37.5%)	247 (62.5%)
30–39	23 (24.5%)	71 (75.5%)	93 (32.6%)	192 (67.4%)
40-50	4 (26.7%)	11 (73.3%)	27 (10.0%)	243 (90.0%)
$\mathbf{MA}^{*}(\mathbf{n}=23,203)^{A}$				
Pregnancy Status	n = 5,2	11 (22.5%)	n = 17,	,992 (77.5%)
	Severe CHD	Not Severe CHD	Severe CHD	Not Severe CHD
Age-Adjusted Proportion Pregnant by CHD Severity	24.6	21.7		
% Severe by Pregnancy Status	1,028 (19.7%)	4,183 $(80.3%)$	3,097 (17.2%)	14,895 (82.8%)
CHD Severity by Pregnancy Status and Age 11–19	198 (22.8%)	670 (77.2%)	1,014~(18.4%)	4,486 (81.6%)
20-29	381 (20.6%)	1471 (69.8%)	710(18.7%)	3,077 (81.3%)
30–39	254 (17.7%)	1184 (82.3%)	582~(16.3%)	2,980 (83.7%)
40-50	195 (18.5%)	858 (81.5%)	791 (15.4%)	4,352 (84.6%)
$NY^{*}(n = 1, 458)^{A}$				
Pregnancy Status	n = 18	6 (12.8%)	n = 1,2	272 (87.2%)
	Severe CHD	Not Severe CHD	Severe CHD	Not Severe CHD
Age-Adjusted Proportion Pregnant by CHD Severity	10.0	21.5		
% Severe by Pregnancy Status	n = 14 (7.5%)	$n = 172 \ (92.5\%)$	n = 267 (21.0%)	n = 1,005 (79.0%)

-
-
5
-
<u>ر</u>
0
<b></b>
$\leq$
a
Man
Manu
Manus
Manusci
Manuscri
vlanuscrip
Manuscript

Author Manuscript

			LTeg	guant	
TOTAL $(n = 26,655)$		Yes n = {	5,672 (21.3%)	No 20;	983 (78.7%)
		Severe CHD 1,126 (19.8%)	Not Severe CHD 4,546 (80.2%)	Severe CHD 3,893 (18.5%)	Not Severe CHD 17,090 (81.5%)
CHD Severity by Pregnancy Status and Age	11–19	<10	43 (93.5%)	202 (23.6%)	653 (76.4%)
	20–29	<10	73 (92.4%)	35 (29.4%)	84 (70.6%)
	30–39	<10	50 (92.6%)	14 (14.3%)	84 (85.7%)
	40–50	<10	<10	16 (8.0%)	184 (92.0%)

 $\dot{\tau}_{\rm Pregnant:}^{\rm t}$  experienced a pregnancy during 2008 to 2010; nonpregnant: did not experience a pregnancy during 2008 to 2010.

\* EU=Emory University; catchment area incl. 5 metro-Atlanta counties: Clayton, Cobb, DeKalb, Fulton and Gwinnett; MA=Massachusetts Dept. of Public Health; catchment area is state-wide; NY=New York State Dept. of Health; catchment area incl. 11 counties: Allegany, Bronx, Cattaraugus, Chautauqua, Erie, Genesee, Monroe, Niagara, Orleans, Westchester & Wyoming

Percent of total by site: EU: 1,994/26,655 = 7.5%; MA: 23,203/26,655=87.0%; NY: 1,458/26,655=5.5%.

<sup>AA</sup> Individuals classified with ICD-9-CM code 745.5 in isolation are not included. Note. Cells with <10 count indicated as <10. Prevalence of gestational complications for women with congenital heart defects (CHD)<sup>M</sup> at 3 surveillance sites, 2008 to 2010<sup>\*\*</sup>

	$EU^* n = 275 (4.9\%)$	$MA^{*} n = 5,211 (91.9\%)$	$NY^* n = 186 (3.3\%)$
Cardiovascular Complications			
Hypertension in Pregnancy	35 (12.7%)	60 (1.2%)	14 (7.5%)
Pre-Eclampsia	20 (7.3%)	44 (0.8%)	12 (6.5%)
Other Cardiovascular Disorders	60 (21.8%)	46 (0.9%)	48 (25.8%)
Non-Cardiovascular Complications			
Preterm Labor	98 (35.6%)	142 (2.7%)	19 (10.2%)
Gestational Diabetes	33 (12.0%)	130 (2.5%)	11 (5.9%)
Anemia in Pregnancy	56 (20.4%)	45 (0.9%)	31 (16.7%)
Hyperemesis	39 (14.2%)	66 (1.3%)	14 (7.5%)
Infectious Disease in Pregnancy	45 (16.4%)	41 (0.8%)	21 (11.3%)
Genitourinary / Gynecology in Pregnancy	51 (18.6%)	39 (0.8%)	23 (12.4%)
Obesity in Pregnancy	28 (10.2%)	35 (0.7%)	<10
Hemorrhage in Pregnancy	60 (21.8%)	120 (2.3%)	36 (19.4%)
Prolonged Pregnancy	23 (8.4%)	42 (0.8%)	24 (12.9%)
Malposition (malpresentation of fetus)	35 (12.7%)	40 (0.8%)	14 (7.5%)
Smoking in Pregnancy	13 (4.7%)	22 (0.4%)	15 (8.1%)
Mental Disorders in Pregnancy	11 (4.0%)	37 (0.7%)	22 (11.8%)
Other Pregnancy Loss	28 (10.2%)	153 (2.9%)	20~(10.8%)
Other Obstetrical Complications	98 (35.6%)	120 (2.3%)	69 (37.1%)

Am J Cardiol. Author manuscript; available in PMC 2020 September 16.

\* EU-Emory University; catchment area includes 5 metro-Atlanta counties: Clayton, Cobb, DeKalb, Fulton and Gwinnett; MA=Massachusetts Department of Public Health; catchment area is state-wide; and NY=New York State Department of Health; catchment area includes 11 counties: Allegany, Bronx, Cattaraugus, Chautauqua, Erie, Genesee, Monroe, Niagara, Orleans, Westchester, and Wyoming

\*\* Data collapsed across CHD severity.

 $^{\prime\prime}$  Individuals classified with ICD-9\_CM code 745.5 in isolation are not included. Cells with <10 count indicated as <10.

# Table 3

Prevalence of cardiovascular co-morbidities for women with congenital heart defects (CHD)<sup>24</sup> by pregnancy during project period, overall and by 2008 to 2010\*\* .... E.

	Hypertension	Hyperlipidemia	Coronary Artery Disease	Stroke, Thrombosis & Other Cardiovascular	Arrhythmias & Conduction Disorders	Venous Disorder / Phlebitis	Heart Failure
Pooled Across Sites (n = 26,655)							
Pregnant n = 5,672 (21.3%)	31.1%	18.7%	10.3%	39.4%	25.0%	6.2%	10.8%
Not Pregnant n = 20,983 (78.7%)	21.0%	14.8%	7.8%	58.6%	33.5%	3.9%	12.2%
p_value	p <0.001	p <0.001	p <0.001	p <0.001	p <0.001	p <0.001	p <0.01
$EU^{*}(n = 1,994)$							
Pregnant n = 275 (13.8%)	13.5%	5.1%	9.1%	51.3%	26.6%	5.8%	7.3%
Not Pregnant n = 1,719 (86.2%)	9.5%	4.9%	5.2%	47.8%	21.5%	3.0%	4.3%
p_value	p <0.05	p <0.918	p <0.05	p <0.279	p <0.063	p <0.05	p <0.05
$MA^{*}(n = 23,203)$							
Pregnant $n = 5,211 (22.5\%)$	32.9%	20.0%	10.6%	38.4%	25.0%	6.4%	11.2%
Not Pregnant n = 17,992 (77.5%)	22.7%	16.3%	8.2%	61.0%	35.8%	4.0%	13.3%
p_value	p <0.001	p <0.001	p <0.001	p <0.001	p <0.001	p <0.001	p <0.001
NY $^{*}(n = 1,458)$							
Pregnant n = 186 (12.8%)	8.6%	1.1%	3.8%	49.5%	21.5%	1.6%	5.9%
Not Pregnant n = 1,272 (87.2%)	12.5%	6.1%	5.3%	39.3%	16.9%	2.8%	6.6%
p_value	p <0.127	p <0.01	p <0.362	p <0.01	p <0.123	p <0.336	p <0.722

Am J Cardiol. Author manuscript; available in PMC 2020 September 16.

EU=Emory University; catchment area incl. 5 metro-Atlanta counties: Clayton, Cobb, DeKalb, Fulton and Gwinnett; MA=Massachusetts Dept. of Public Health; catchment area is state-wide; NY=New York State Dept. of Health; catchment area incl. 11 counties: Allegany, Bronx, Cattaraugus, Chautauqua, Erie, Genesee, Monroe, Niagara, Orleans, Westchester & Wyoming.

\*\* Data collapsed across CHD severity.

 $^{\prime\prime}$  Individuals classified with ICD-9\_CM code 745.5 in isolation are not included.

Author Manuscript

## Table 4

Prevalence of noncardiovascular co-morbidities for women with congenital heart defects (CHD) by pregnancy during project period, pooled across and by 3 surveillance sites, 2008 to  $2010^{**}$ 

	Ove	rall n = 26,655		E	U* n = 1,994		M	A n = 23,203		N	$N^* n = 1,458$	
	Pregnant n = 5,672 (21.3%)	Not Pregnant n = 20,983 (21.3%)	p_value	Pregnant n = 275 (13.8%)	Not Pregnant n = 1,192 (86.2%)	p_value	Pregnant n = 5,211 (22.5%)	Not Pregnant n = 17,992 (21.3%)	p_value	Pregnant n = 186 (12.8%)	Not Pregnant n = 1,272 (87.2%)	p_value
Diabetes Mellitus	23.6%	17.2%	<0.001	6.9%	3.0%	0.001	25.3%	19.3%	<0.001	<10	5.5%	su
Other Endocrine	16.5%	12.0%	<0.001	6.2%	4.0%	$N_{S}$	17.5%	13.1%	<0.001	<10	6.5%	su
<b>Birth Defects</b>	20.4%	15.8%	<0.001	8.7%	12.3%	$N_{\rm S}$	21.5%	16.1%	<0.001	5.9%	15.3%	0.001
Hematologic	22.5%	17.6%	<0.001	27.3%	10.7%	<0.001	22.2%	18.7%	<0.001	24.7%	12.0%	<0.001
Neoplasms	18.8%	14.6%	<0.001	21.5%	6.5%	<0.001	19.1%	15.9%	<0.001	<10	7.2%	su
Gastrological	36.4%	31.3%	<0.001	33.8%	15.3%	<0.001	36.7%	33.2%	<0.001	31.7%	25.2%	us
Other Genitourinary	7.7%	9.3%	<0.001	6.2%	2.8%	0.01	7.9%	10.4%	<0.001	<10	3.8%	su
CNS	12.6%	13.3%	us	5.5%	5.0%	su	13.3%	14.7%	0.01	5.9%	5.8%	su
Immunologic/ Rheumatologic/ Allergy	3.3%	3.5%	su	3.6%	1.5%	0.01	3.4%	3.7%	su	<10	2.9%	su
Respiratory/ Pulmonary	40.5%	38.2%	0.01	38.6%	25.5%	<0.001	40.9%	40.1%	us	30.7%	29.3%	su
Musculoskeletal	43.6%	36.4%	<0.001	28.4%	14.5%	<0.001	44.9%	39.6%	su	26.9%	20.4%	0.05
Injury/Trauma	16.9 %	15.9%	ns	17.5%	8.0%	<0.001	16.5%	16.1%	su	25.8%	23.5%	us
Infectious Disease	29.7%	21.8%	<0.001	45.5%	17.9%	<0.001	28.6%	21.6%	<0.001	37.1%	30.4%	su
Mental Health	42.7%	33.9%	<0.001	22.2%	10.8%	< 0.001	44.3%	37.0%	<0.001	30.7%	20.2%	0.001
Genitourinary / Gynecological	38.7%	29.4%	<0.001	78.9%	16.1%	<0.001	36.2%	31.4%	<0.001	48.9%	18.7%	<0.001
CHD = Congenital Heat	rt Defect.											

Am J Cardiol. Author manuscript; available in PMC 2020 September 16.

\* EU=Emory University; catchment area incl. 5 metro-Atlanta counties: Clayton, Cobb, DeKalb, Fulton and Gwinnett; MA=Massachusetts Dept. of Public Health; catchment area is state-wide; and NY=New York State Dept. of Health; catchment area incl. 11 counties: Allegany, Bronx, Cattaraugus, Chautauqua, Erie, Genesee, Monroe, Niagara, Orleans, Westchester & Wyoming.

\*\* Data collapsed across CHD severity.

 $^{\prime\prime}$  Individuals classified with ICD-9\_CM code 745.5 in isolation are not included.